Central Lab of Shenzhen Pingshan People's Hospital, Shenzhen, China.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):116-126. doi: 10.26355/eurrev_202101_24355.
Dysregulated lipid metabolism has been reported in the progression of hepatocellular carcinoma (HCC). In the present study, we investigated the molecular characteristics of lipid-metabolism-related genes (IMRGs) as prognostic markers for HCC.
Multi-dimensional bioinformatics analyses were performed to comprehensively analyze IMRGs, and to construct prognostic prediction signatures.
Data of 770 HCC patients and their corresponding 776 IMRGs were downloaded from three databases. Patients were classified into 2 molecular clusters that were associated with overall survival, clinical characteristics, and immune cells. The biological functions of the IMRGs differentially expressed between the 2 clusters were associated with tumor-related metabolic pathways. A 6 IMRG signature (6-IS), consisting of FMO3, SLC11A1, RNF10, KCNH2, ME1, and ZIC2, was established as an independent prognostic factor for HCC. The performance of the signature of 6-IS prognostic was verified in a validation set and compared to an external data set. It was revealed that the 6-IS could effectively predict the prognosis of patients with HCC.
This study provides new insights into the role of IMRGs in the pathogenesis of HCC, and presents a novel signature (6-IS) to predict the prognosis of HCC.
已有研究报道，脂质代谢失调与肝细胞癌（HCC）的进展有关。本研究旨在探讨脂质代谢相关基因（IMRGs）作为 HCC 预后标志物的分子特征。
通过多维生物信息学分析，全面分析 IMRGs 并构建预后预测特征。
从三个数据库中下载了 770 名 HCC 患者及其对应的 776 个 IMRGs 数据。患者被分为 2 个分子簇，与总生存期、临床特征和免疫细胞相关。2 个簇中差异表达的 IMRGs 的生物学功能与肿瘤相关的代谢途径有关。建立了一个由 6 个 IMRG（FMO3、SLC11A1、RNF10、KCNH2、ME1 和 ZIC2）组成的 6-IS signature，作为 HCC 的独立预后因素。在验证集和外部数据集对 6-IS 预后模型的性能进行了验证，结果表明 6-IS 能够有效预测 HCC 患者的预后。
本研究深入探讨了 IMRGs 在 HCC 发病机制中的作用，并提出了一个新的signature（6-IS）来预测 HCC 的预后。
